An ambispective study published in "Acta Dermato-Venereologica" shed light on real-life outcomes associated with Omalizumab therapy and underscored the potential significance of  immunoglobulin E (IgE)-mediated pathways in solar urticaria, with high-affinity IgE receptor (FcεRI) potentially serving as a biomarker for Omalizumab response.

This research examined the clinical and therapeutic characteristics of a solar urticaria patient group over a long-term period, specifically focusing on the usage of Omalizumab and its outcomes.  Utilizing the Urticaria Control Test (UCT), the study also scrutinized the response to Omalizumab therapy by estimating the levels of the FcεRI. Carried out at a single center, this observational study encompassed 41 individuals diagnosed with solar urticaria, with a median follow-up of sixty months.

Thirteen of these volunteers received Omalizumab, with a median treatment duration of 48 months. Following Omalizumab use, there was a notable decrease in baseline FcεRI levels across all the  patients. This was accompanied by a median increase in UCT scores. The drug survival rate at 48 months stood at 88.9%. However, employing a protocol to gradually curtail Omalizumab dosage only resulted in sustained discontinuation of the medication in one participant. Furthermore, those prescribed Omalizumab and those without remission exhibited lower median basal UCT scores (p < 0.01).